In addition, a significant study on the mechanism of treatment for mantle cell lymphoma (MCL) indicated that the inactivation of the Wnt/β-catenin signaling pathway and downregulation of DNMT1 synergistically suppressed MCL, and these results could guide the dosing in the clinical treatment of MCL (Li et al., 2017). The gene discussed is DNMT1; the disease is mantle cell lymphoma.